What is William Blair’s Forecast for BMRN Q1 Earnings?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for BioMarin Pharmaceutical in a report issued on Thursday, February 20th. William Blair analyst S. Corwin expects that the biotechnology company will earn $0.93 per share for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. William Blair also issued estimates for BioMarin Pharmaceutical’s Q2 2026 earnings at $0.97 EPS and Q3 2026 earnings at $0.98 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The business had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million.

Several other research firms also recently issued reports on BMRN. Canaccord Genuity Group dropped their target price on BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating on the stock in a research report on Wednesday, October 30th. Bank of America increased their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Robert W. Baird dropped their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Finally, Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price on the stock in a research report on Monday. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $69.00 on Monday. The firm has a market cap of $13.15 billion, a price-to-earnings ratio of 31.36, a price-to-earnings-growth ratio of 0.61 and a beta of 0.28. The stock has a fifty day simple moving average of $64.95 and a two-hundred day simple moving average of $70.61. BioMarin Pharmaceutical has a 1-year low of $60.63 and a 1-year high of $94.85. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. Merit Financial Group LLC bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $317,000. Assenagon Asset Management S.A. grew its stake in shares of BioMarin Pharmaceutical by 461.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after buying an additional 502,695 shares during the last quarter. Wedmont Private Capital bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $430,000. Swedbank AB grew its stake in shares of BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company’s stock valued at $28,403,000 after buying an additional 43,593 shares during the last quarter. Finally, EULAV Asset Management grew its stake in shares of BioMarin Pharmaceutical by 12.9% during the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock valued at $9,208,000 after buying an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.